Fact-checked by Grok 2 weeks ago

MMR vaccine

The MMR vaccine is a trivalent live attenuated vaccine that immunizes against measles, mumps, and rubella viruses, three highly contagious diseases that can cause severe complications including encephalitis, deafness, and congenital rubella syndrome. Developed by Merck virologist Maurice Hilleman by combining individual vaccines licensed in the 1960s, it was introduced in 1971 as a single subcutaneous injection typically administered in two doses during childhood. Clinical data indicate two doses confer 97% efficacy against measles, 88% against mumps, and at least 97% against rubella, contributing to near-elimination of these diseases in regions with high vaccination coverage. Post-licensure surveillance and modeling show vaccination averted millions of cases and deaths globally, with U.S. measles cases dropping from hundreds of thousands annually pre-1963 to dozens by the 2000s following widespread MMR use. While generally safe, with most adverse events limited to mild fever or rash in 5-15% of recipients, rare serious reactions include febrile seizures (1 in 3,000-4,000 doses) and thrombocytopenia (1 in 30,000-40,000). A major controversy arose from a 1998 Lancet paper by Andrew Wakefield et al. suggesting an MMR-autism link, which was retracted in 2010 after revelations of data falsification, undeclared conflicts, and ethical breaches; subsequent large-scale studies involving millions of children found no causal connection. Despite refutation, the episode fueled vaccine hesitancy and measles resurgence in under-vaccinated communities.

Composition

Viral Components

The MMR vaccine incorporates live attenuated viruses of measles, mumps, and rubella to elicit protective immunity through controlled replication that mimics aspects of natural infection without causing clinical disease. The measles component utilizes the Enders' attenuated Edmonston strain, originally isolated from a patient in 1954 and further attenuated through serial passages in chick embryo cell cultures and human diploid cells, reducing neurovirulence while retaining the ability to induce neutralizing antibodies and T-cell responses. The mumps component employs the Jeryl Lynn strain, derived from a natural isolate in 1963 and minimally passaged in chick embryo fibroblasts to diminish pathogenicity, primarily stimulating humoral immunity via IgG production against viral surface proteins. The rubella component features the RA 27/3 strain, developed in 1965 from human embryonic lung fibroblasts and propagated in WI-38 human diploid cells, which enhances immunogenicity by preserving key epitopes for both antibody and cell-mediated responses. These attenuated strains undergo adaptation to achieve a balance between replication competence—necessary for antigen presentation and immune memory formation—and avirulence, typically via 40–85 passages in heterologous cell lines that select for mutations altering tropism and replication kinetics. In vaccine recipients, the viruses express structural proteins (e.g., measles hemagglutinin and fusion proteins) that trigger B-cell activation for seroconversion and CD4+/CD8+ T-cell priming for long-term surveillance, with post-vaccination studies reporting measles antibody seroconversion rates of 93–97% after a single dose in seronegative children aged 12 months or older. Mumps seroconversion similarly reaches 88–100%, while rubella achieves 98–100%, reflecting the strains' capacity to generate titers comparable to those from subclinical infection. This immunogenicity stems from the viruses' partial replication in lymphoid tissues, amplifying antigen exposure without systemic spread.

Manufacturing and Preservatives

The MMR vaccine is manufactured by propagating live attenuated strains of measles, mumps, and rubella viruses in human diploid cell lines, primarily WI-38 or MRC-5, which are derived from fetal lung fibroblasts established in the 1960s. These cell lines support efficient viral replication without serum in the growth medium, followed by harvest, clarification, and purification steps to eliminate cellular debris, adventitious agents, and host cell proteins, ensuring the final bulk drug substance meets purity standards. For Merck's M-M-R II, the rubella component (Wistar RA 27/3 strain) is specifically adapted and propagated in WI-38 cells, with manufacturing inputs like recombinant human albumin and fetal bovine serum rigorously tested for contaminants prior to use. Formulation involves blending the purified virus bulks with stabilizers to preserve viral potency during lyophilization and storage. Common stabilizers include sorbitol (14.5 mg per dose in M-M-R II), hydrolyzed gelatin (14.5 mg), and sucrose (1.9 mg), which prevent denaturation and maintain stability at refrigerator temperatures (2–8°C). GlaxoSmithKline's Priorix formulation similarly incorporates amino acids, lactose, and mannitol as cryoprotectants, along with trace bovine serum albumin and ovalbumin from production media, but avoids gelatin to reduce potential hypersensitivity risks. Neither M-M-R II nor Priorix contains thimerosal or other mercury-based preservatives in the final product; however, residual neomycin sulfate (approximately 25 mcg per dose) persists from manufacturing to inhibit bacterial overgrowth during cell culture, though it serves no preservative function post-formulation. Quality control encompasses batch-specific testing for sterility, potency (via plaque assays or seroconversion correlates), identity, and absence of contaminants, adhering to FDA and EMA monographs. WHO-prequalified MMR vaccines, including variants from Merck and GSK, undergo independent lot-release testing by national control laboratories for consistency, with specifications ensuring viral titers exceed minimum thresholds (e.g., ≥3 log10 TCID50 for measles per dose). These processes yield high manufacturing consistency, as evidenced by post-licensure stability data showing retained immunogenicity beyond labeled shelf life in controlled studies.

Targeted Diseases

Measles Characteristics and Burden

Measles is caused by the measles virus, an enveloped, non-segmented, single-stranded, negative-sense RNA virus belonging to the genus Morbillivirus within the family Paramyxoviridae. The virus exclusively infects humans, with no known animal reservoir, and spreads via direct contact with infectious respiratory droplets or airborne particles from coughing, sneezing, or talking. It exhibits extreme contagiousness, with a basic reproduction number (R0) ranging from 12 to 18 in susceptible populations, meaning each infected individual can transmit the virus to 12 to 18 others under ideal conditions. The typical incubation period lasts 10 to 14 days, after which prodromal symptoms emerge, including high fever (often exceeding 40°C), malaise, the "three Cs" (cough, coryza, and conjunctivitis), and pathognomonic Koplik's spots—small white lesions on the buccal mucosa. A erythematous maculopapular rash then appears, starting on the face and spreading cephalocaudally over 3 to 4 days. Complications arise in about 30% of unvaccinated cases, with bacterial superinfections such as pneumonia (the primary cause of death, especially in developing regions) and otitis media being common; diarrhea affects up to 8% of cases. Neurological involvement includes acute encephalitis in approximately 1 per 1,000 cases, carrying a 15% mortality rate and risking permanent sequelae like intellectual disability or epilepsy in survivors. Before vaccine availability, measles exacted a heavy toll in the United States, with an estimated 3 to 4 million infections yearly, around 500,000 reported cases, roughly 48,000 hospitalizations, and 400 to 500 deaths annually, primarily from respiratory and neurological complications. Globally, prior to widespread immunization efforts, the disease caused over 2.6 million deaths per year in 1980, mostly among malnourished children under age 5 in low-resource settings where case-fatality ratios reached 5 to 10%. Subacute sclerosing panencephalitis (SSPE), a rare delayed sequela, manifests as a fatal neurodegenerative disorder 6 to 10 years post-infection due to persistent viral replication in the central nervous system. Cohort studies estimate its incidence at 4 to 11 cases per 100,000 measles infections, with risks escalating to 18 per 100,000 or higher if infection occurs before age 2, underscoring the virus's potential for lifelong consequences even in survivors of acute illness.

Mumps Characteristics and Burden

Mumps is an acute contagious disease caused by the mumps virus, a single-stranded RNA virus in the genus Rubulavirus of the Paramyxoviridae family. The virus primarily targets the salivary glands, leading to characteristic parotitis—inflammation and swelling of the parotid glands—in approximately 70% to 90% of symptomatic cases, often preceded by a prodromal phase of fever, headache, and malaise lasting 1 to 2 days. Incubation typically spans 12 to 25 days, with transmission occurring via respiratory droplets or direct contact with infected saliva; up to 40% of infections may be subclinical, facilitating undetected spread. Complications arise when the virus disseminates beyond the salivary glands, affecting organs such as the testes, ovaries, pancreas, and central nervous system. Orchitis, the most common severe complication in post-pubertal males, occurs in 15% to 30% of cases and can result in testicular swelling, pain, and potential atrophy in up to 50% of affected testes, contributing to subfertility through oligospermia or asthenospermia, though complete sterility is uncommon. Oophoritis affects fewer than 5% of post-pubertal females, with pancreatitis reported in 3% to 7%. Neurological involvement includes aseptic meningitis in 1% to 10% of cases and encephalitis in 0.02% to 0.3%, while unilateral sensorineural hearing loss—often permanent—occurs in approximately 1 in 20,000 infections, potentially underreported due to its rarity and association with subclinical cases. Prior to widespread vaccination, mumps imposed a substantial public health burden in the United States, with an estimated 150,000 to 162,000 reported cases annually during the early 1960s, alongside underreported infections leading to biennial or triennial epidemics affecting up to 90% of children by adolescence. Globally, in regions with low vaccination coverage, mumps remains endemic, causing outbreaks with high attack rates among unvaccinated populations, particularly young adults, and contributing to morbidity from complications like orchitis and neurological sequelae. Recent U.S. outbreaks, such as those in 2016–2017 exceeding 6,000 cases primarily among young adults, underscore the disease's potential for resurgence and the persistent risks of complications even in vaccinated cohorts due to factors like waning immunity.

Rubella Characteristics and Burden

Rubella is caused by the rubella virus, a single-stranded RNA virus in the genus Rubivirus of the family Togaviridae. The infection typically presents as a mild illness in children, featuring a maculopapular rash starting on the face and spreading to the trunk and limbs, accompanied by low-grade fever, sore throat, headache, conjunctivitis, and postauricular or suboccipital lymphadenopathy. Adults, particularly women, may experience more pronounced symptoms including arthralgia or arthritis lasting days to months. Mortality from rubella is rare, with death primarily occurring in cases of encephalitis or other complications, though the disease's public health significance stems from its teratogenic effects during pregnancy rather than direct lethality. Congenital rubella syndrome (CRS) arises when maternal rubella infection occurs during pregnancy, with the highest risk in the first trimester, affecting up to 85% of fetuses exposed in the initial 12 weeks. CRS manifests as a triad of sensorineural deafness, congenital cataracts, and congenital heart defects, alongside risks of microcephaly, mental retardation, and other multisystem anomalies; infection before 18 weeks gestation confers substantial fetal risk. Approximately 25-50% of rubella infections are asymptomatic, enabling undetected transmission via respiratory droplets or direct contact with nasopharyngeal secretions. In the pre-vaccine era, rubella imposed a heavy burden, exemplified by the 1964-1965 United States epidemic, which infected an estimated 12.5 million individuals, resulted in approximately 20,000 CRS cases, 11,000 fetal losses (including therapeutic abortions and stillbirths), and 2,100 neonatal deaths. Globally, rubella persists in regions without widespread vaccination, contributing to ongoing CRS incidence; for instance, modeled estimates indicate thousands of annual CRS cases in unvaccinated areas, underscoring the need for targeted immunization to interrupt transmission. Mathematical modeling studies estimate the herd immunity threshold for rubella at approximately 83-85%, reflecting the virus's basic reproduction number (R0) of around 6-7, beyond which sustained outbreaks are unlikely in susceptible populations.

Efficacy

Laboratory and Trial Efficacy

The MMR vaccine demonstrates high immunogenicity in controlled clinical trials, with seroconversion rates—defined as the development of protective antibody levels post-vaccination—typically exceeding 95% for measles and rubella components after a single dose, while mumps seroconversion ranges from 74% to 91%. These rates are measured via assays such as hemagglutination inhibition for mumps and rubella, and plaque reduction neutralization tests (PRNT) for measles, where a titer of at least 1:120 is often correlated with protection against clinical disease. Early randomized controlled trials (RCTs) in the 1970s, including those evaluating the combined MMR formulation, confirmed these outcomes in healthy children aged 12-15 months, with measles vaccine efficacy reaching 95-100% in preventing viremia or rash upon natural exposure or controlled viral challenge. For the measles component (Edmonston-Enders strain), pre-licensure trials from the 1960s, such as those involving over 1,000 children, showed 95% seroconversion after one dose, with challenge studies demonstrating near-complete resistance to wild-type virus infection in vaccinated subjects, as evidenced by absent or attenuated symptoms and lack of transmission. The mumps component (Jeryl Lynn strain) exhibited more variable results in RCTs, with seroconversion rates of 74-91% post-first dose, attributed to differences in assay sensitivity and baseline immunity, though neutralization assays indicate functional antibodies sufficient for short-term protection. Rubella (RA 27/3 strain) consistently achieved 90-100% seroconversion, with trials confirming hemagglutination inhibition titers above 1:8 as protective against congenital rubella syndrome risk. A second dose, administered 4-6 weeks to years later, boosts seroconversion to 97% or higher across components, particularly enhancing measles and mumps responses in non-responders from the first dose. Follow-up data from trial cohorts indicate durable antibody persistence: measles and rubella immunity remains lifelong in most recipients, with geometric mean titers stable over decades in serological surveillance; mumps antibodies, however, show potential waning after 10-15 years, as noted in meta-analyses of long-term immunogenicity studies. These findings from RCTs underscore the vaccine's laboratory efficacy but highlight mumps as the component with greatest variability in sustained humoral response.

Real-World Effectiveness and Limitations

Observational studies post-licensure have demonstrated high real-world effectiveness of the MMR vaccine against measles, with two doses conferring approximately 97% protection against disease and 96% effectiveness against hospitalization during outbreaks, as evidenced by a retrospective cohort analysis in Spain involving 1,394 participants amid a measles resurgence. One dose yields about 93-95% effectiveness, underscoring the value of the second dose in closing immunity gaps observed in seroprevalence data. Long-term cohort evaluations indicate that two-dose effectiveness against measles remains robust, with only slight degradation even decades post-vaccination, though breakthrough cases can arise in high-exposure scenarios like travel-related importations or pockets of under-vaccination. For mumps, real-world vaccine effectiveness (VE) with two doses is estimated at 86-88%, yet outbreaks have occurred in highly vaccinated populations, such as U.S. college campuses in 2016-2017, where up to 89% of cases involved individuals with documented two prior doses. These events, including over 5,000 doses administered reactively in Indiana universities, highlight limitations including waning immunity, with antibody levels declining over 10 years in two- and three-dose recipients and VE potentially dropping 10-20% beyond a decade post-vaccination. Genotype mismatches contribute, as the Jeryl Lynn vaccine strain (genotype A) exhibits reduced cross-neutralization against predominant wild-type genotype G strains circulating in outbreaks, enabling transmission among vaccinated individuals despite overall population-level control. A third dose has shown added protection in outbreak settings, reducing mumps risk compared to two doses alone. Rubella effectiveness mirrors measles, with two doses providing near-complete protection in real-world surveillance, and breakthroughs rare except in unvaccinated or immunocompromised groups; limitations are minimal but include potential waning in seropositivity rates over time, as detected in multi-country surveys. Across components, one-dose regimens show 10-20% lower VE than two doses, with time since last vaccination inversely correlating with protection, particularly for mumps, prompting recommendations for outbreak responses or high-risk settings. Seroprevalence studies quantify waning, such as an average 9.7% annual decline in measles antibody titers post-first dose in children aged 1.5-10 years, though two-dose schedules mitigate this more effectively long-term. Factors like close-contact environments amplify breakthrough risks, emphasizing the vaccine's role in herd immunity thresholds above 95% coverage for sustained elimination.

Administration

Dosing Schedules

The recommended dosing schedule for the MMR vaccine in the United States, as established by the Centers for Disease Control and Prevention (CDC), consists of two doses for children: the first administered at 12 through 15 months of age and the second at 4 through 6 years of age. This regimen applies to the combined measles, mumps, and rubella vaccine, with doses separated by a minimum interval of 28 days to allow for adequate immune response development. The two-dose schedule addresses primary vaccine failure, where approximately 5-7% of recipients do not achieve protective immunity after the initial dose against measles, with seroconversion rates improving to over 97% following the second dose. The timing of the first dose coincides with the waning of maternal antibodies, typically by 12 months, which could otherwise interfere with vaccine-induced immunity if administered earlier in infancy. For mumps and rubella components, the second dose similarly enhances long-term protection, reducing outbreak risks in school-aged populations where transmission occurs. Catch-up vaccination is advised for individuals who missed prior doses, including adults born in 1957 or later without documented evidence of immunity, who should receive one or two doses depending on risk factors such as occupational exposure or international travel. Preschool-aged children or others requiring earlier boosting may receive the second dose as soon as 28 days after the first, though routine scheduling prioritizes age-appropriate intervals for optimal population-level efficacy. Internationally, the World Health Organization (WHO) endorses two doses of measles-containing vaccine for all children, but schedules vary by epidemiology: in high-burden or outbreak-prone regions, the first dose may be given at 9 months to accelerate herd immunity, followed by a second at 15-18 months, whereas higher-income settings align closely with the 12-15 month initial dosing to minimize interference from maternal antibodies. These adaptations reflect local disease incidence data, with combined MMR formulations used where rubella and mumps control is prioritized alongside measles elimination goals.

Precautions and Contraindications

The MMR vaccine, being a live attenuated virus preparation, carries absolute contraindications in individuals with severe immunocompromise, such as those with congenital immunodeficiency, active untreated tuberculosis, or receiving high-dose systemic immunosuppressive therapy including corticosteroids equivalent to ≥2 mg/kg/day of prednisone for ≥2 weeks. Pregnancy is also an absolute contraindication due to theoretical risks to the fetus from viral replication, with women advised to avoid conception for 28 days post-vaccination. A history of anaphylaxis to vaccine components, including neomycin (present at 25 μg per dose) or hydrolyzed gelatin (14.5 mg per dose), warrants exclusion, as case reports document gelatin-mediated anaphylaxis following MMR administration. Precautions apply in scenarios where vaccination may proceed after individualized risk-benefit evaluation. Egg allergy does not contraindicate MMR, as the vaccine contains negligible egg protein (<0.05 ng/dose from chick embryo fibroblast culture); multiple studies, including administration to over 2,700 egg-allergic children, report no increased anaphylaxis risk compared to non-allergic recipients. Recent receipt of antibody-containing blood products or immunoglobulins (e.g., within 3-11 months, depending on product) is a precaution due to potential neutralization of vaccine viruses, though safety data confirm no excess adverse events. Personal or family history of febrile seizures merits caution, as vaccine-associated fever occurs in 5-15% of recipients and could theoretically trigger events, but cohort data show no causal link to new-onset epilepsy. In mild immunocompromise, such as asymptomatic HIV infection with CD4 counts ≥15% or low-dose immunosuppression, empirical safety data support vaccination; prospective studies in immunosuppressed cohorts (e.g., under maintenance therapy) report no significant excess adverse events beyond background rates, with VAERS analyses aligning on rarity of complications like disseminated infection. Prior anaphylaxis to a previous MMR dose remains a strict exclusion, but moderate acute illness (e.g., low-grade fever) is not, provided deferral does not increase disease exposure risk.

Safety Profile

Mild and Common Reactions

Local reactions at the injection site, such as soreness, redness, erythema, or swelling, are the most frequently reported mild adverse events following MMR vaccination, occurring in approximately 10-16% of recipients and typically resolving within 2-3 days without intervention. These symptoms are more common after the first dose due to lack of prior immunity and are generally mild, with rates ranging from 6-48% across various studies in children aged 12 months to 6 years. Systemic reactions include fever and mild rash, affecting 5-15% and 2-5% of vaccinees, respectively, with onset peaking 7-12 days post-vaccination due to replication of the live attenuated viruses. Fever rates are higher after the initial dose (up to 15% in some cohorts) compared to boosters, and rashes are non-infectious, lasting about 2 days. Swelling of the parotid glands (parotitis), linked to the mumps component, occurs in 1-3% of cases, presenting as mild, unilateral or bilateral tenderness resolving spontaneously. Temporary arthralgia or arthritis, primarily from the rubella component, affects up to 25% of non-immune post-pubertal females, emerging 1-3 weeks after vaccination and lasting about 2 days, with lower incidence in children and males. Overall, more than 99% of these mild reactions self-resolve without medical treatment, as documented in Vaccine Safety Datalink surveillance and clinical trials. Reactions are less frequent in younger children and after subsequent doses, reflecting partial immunity from prior exposure.

Serious Adverse Events

The MMR vaccine is associated with rare serious adverse events, primarily febrile seizures and immune thrombocytopenic purpura (ITP). Febrile seizures occur at a rate of approximately 1 per 3,000 to 4,000 doses, typically 7–10 days after the first dose in children aged 12–23 months. ITP, a temporary drop in platelet count that can lead to bleeding, follows vaccination at a rate of about 1 per 30,000–40,000 doses, usually within 6 weeks, with most cases resolving without long-term sequelae. Anaphylaxis, an immediate hypersensitivity reaction, occurs in fewer than 5–10 cases per million doses, often linked to vaccine components like gelatin or neomycin. Large-scale reviews, including the 2012 Institute of Medicine (now National Academy of Medicine) report, have found no evidence of a causal association between MMR vaccination and Guillain-Barré syndrome or acute encephalitis beyond background rates. Similarly, post-licensure surveillance data from systems like the Vaccine Safety Datalink show no elevated risk for these outcomes attributable to the vaccine. The Vaccine Adverse Event Reporting System (VAERS), a passive surveillance tool, captures unverified reports of potential events but cannot establish causality due to underreporting of mild cases, overreporting of coincidental events, and lack of denominator data for incidence calculation. Empirical comparisons indicate that risks from natural infection substantially exceed those from vaccination; for instance, measles encephalitis develops in approximately 1 per 1,000 cases of wild-type infection, with a 15–25% mortality or severe disability rate among affected individuals, whereas no such vaccine-induced encephalitis has been causally confirmed in immunocompetent recipients. These vaccine-related risks, while documented through controlled studies and active surveillance, remain orders of magnitude lower than disease complications, supporting net safety in population-level analyses.

Controversies

Autism Causation Claims

In 1998, Andrew Wakefield and colleagues published a case series in The Lancet describing 12 children with developmental regression and gastrointestinal symptoms, in which parents of eight reported onset following MMR vaccination, hypothesizing a possible link via persistent measles virus in the gut leading to autism-like behaviors.11096-0/fulltext) The paper, lacking controls or causal proof, prompted parental concerns and contributed to declining MMR uptake in the UK, correlating with measles outbreaks exceeding 1,000 cases annually by 2008. Investigations later revealed ethical violations, undeclared conflicts (Wakefield received funding from lawyers suing vaccine makers), and data falsification, leading to the paper's full retraction by The Lancet in 2010 and Wakefield's license revocation by the UK General Medical Council for misconduct. Subsequent epidemiological research has consistently found no causal association. A 2019 Danish cohort study of 657,461 children born 1999–2010 showed no increased autism risk among MMR-vaccinated children (adjusted hazard ratio 0.93; 95% CI, 0.85–1.02), including in subgroups like those with sibling autism history or autism risk factors, with follow-up to 2013. An earlier 2002 Danish study of 537,303 children similarly reported no link (relative risk 0.92 for vaccinated vs. unvaccinated). Meta-analyses of over 1.2 million children across multiple studies, including randomized and observational designs, confirm null associations, with odds ratios near 1.0 and no evidence of timing-related triggers. Proponents of a link, including some parent advocacy groups, cite anecdotal reports of regression coinciding with MMR administration at 12–15 months, when early autism signs often emerge, and historical thimerosal exposure (a mercury preservative phased out of most U.S. childhood vaccines by 2001). However, autism diagnosis rates did not decline post-thimerosal removal; California data showed continued increases from 6.2 per 1,000 births in 1999 to 10.8 in 2002, attributable to improved awareness and broadened criteria rather than environmental factors. Twin studies indicate 70–90% heritability for autism spectrum disorder, with prenatal genetic and neurodevelopmental origins preceding vaccination age, undermining temporal correlations as evidence of causation. Despite retraction and refutations from independent bodies like the Institute of Medicine (2004 report rejecting causation after reviewing 14 large studies), claims persist in some online communities and legal filings, with the Wakefield paper cited over 500 times post-retraction, often ignoring methodological flaws in favor of perceived plausibility over population-level data. This divergence highlights challenges in countering confirmation bias, though causal realism favors null hypotheses absent direct mechanistic evidence, as vaccination timing overlaps naturally with autism's typical manifestation window without implying etiology.

Other Health Associations and Vaccine Failures

Claims have been made regarding associations between the MMR vaccine and encephalopathies, particularly in individuals with underlying mitochondrial disorders. In the 2008 Hannah Poling case, a U.S. federal vaccine court conceded that the MMR vaccine, administered on March 21, 2000, aggravated her pre-existing mitochondrial enzyme deficit, resulting in encephalopathy with features of autism spectrum disorder; the family received compensation exceeding $1.5 million. This rare interaction highlights potential vulnerabilities in susceptible subgroups, but large-scale epidemiological studies, including reviews by the Institute of Medicine, have found no evidence of population-level causality between MMR vaccination and encephalopathies or seizures beyond transient febrile events. Vaccine failures, where infection occurs despite vaccination, occur primarily due to secondary failure from waning immunity rather than primary non-response. For measles, two doses of MMR confer approximately 97% effectiveness, implying breakthrough infections in about 3% of recipients, often presenting with milder symptoms and lower complication rates compared to unvaccinated cases. These breakthroughs have been documented in outbreaks, such as the 2024 Chicago cluster where 19 of 67 cases were in two-dose recipients. Mumps outbreaks in highly vaccinated populations underscore limitations in the vaccine's durability, particularly for the mumps component. In 2019, England reported over 3,000 confirmed cases, many among young adults born in the late 1990s with two-dose coverage exceeding 80%, attributed to waning immunity and circulating strains mismatched to vaccine genotypes. Similarly, U.S. outbreaks from 2006–2019 affected vaccinated adolescents and young adults, with median vaccination rates of 87% among pediatric cases, highlighting secondary failure rates potentially over 10% after 15–20 years. Empirical data indicate waning MMR-induced immunity, with measles antibody titers declining at 9.7% per year post-first dose and mumps protection eroding faster, contributing to outbreaks despite high coverage. Natural infection induces more robust, lifelong immunity with higher neutralizing antibody persistence compared to vaccination, potentially conferring advantages in transmission dynamics under low-prevalence conditions where herd effects rely on durable individual protection. Strain evolution and suboptimal boosting in vaccinated hosts further exacerbate these shortfalls, as observed in genotype shifts driving mumps resurgence.

Debates on Over-Reliance and Mandates

Advocates for MMR vaccine mandates argue that compulsory policies are essential to achieve the high population coverage required for herd immunity against measles, estimated at 95% due to the virus's basic reproduction number of approximately 15. In the 2019 U.S. measles outbreaks, 89% of cases occurred in unvaccinated individuals or those with unknown vaccination status, underscoring how pockets of non-compliance can facilitate transmission even in low-incidence settings. Proponents contend that mandates, by minimizing exemptions, prevent outbreaks that disproportionately affect vulnerable groups like infants too young to vaccinate, prioritizing collective risk reduction over individual choice. Critics of mandates highlight that they overlook vaccine limitations, such as breakthrough infections in fully vaccinated individuals, which, while often milder, demonstrate imperfect protection and potential for transmission. Natural immunity acquired from prior measles infection confers lifelong protection, contrasting with vaccine-induced immunity that can wane over time, particularly if primary vaccination occurs early or without boosters. Ethically, mandates are challenged for infringing on bodily autonomy and informed consent, coercing medical interventions with rare but documented risks, even when individual disease risk is low, and potentially incentivizing pharmaceutical priorities over nuanced risk assessment. Empirically, states permitting non-medical exemptions have correlated with higher outbreak incidence, yet stringent mandates have coincided with rising vaccine hesitancy, including for routine childhood immunizations like MMR, exacerbated post-2020 by perceived overreach in pandemic policies. Parental hesitancy toward MMR increased alongside COVID-19 vaccine distrust, with surveys showing delays or skips in childhood vaccinations linked to broader fatigue from coercive measures, potentially undermining long-term compliance more than exemptions alone. This backlash illustrates a causal trade-off where mandates may suppress immediate non-compliance but erode public trust, fostering cycles of resistance that complicate sustained herd immunity efforts.

History

Development and Early Trials

The measles vaccine component was pioneered by John F. Enders and colleagues, who isolated the Edmonston strain in 1954 and attenuated it through serial passages in human and non-human primate kidney cells followed by chick embryo fibroblast cultures to achieve a balance of immunogenicity and reduced virulence. This live attenuated vaccine was licensed in the United States in 1963 after initial clinical trials in children, including institutionalized populations, demonstrated seroconversion rates exceeding 95% and protection against viral challenge with minimal severe reactions. Early safety assessments involved thousands of participants, confirming attenuation effectiveness via reduced clinical symptoms compared to wild-type infection while eliciting durable antibody responses. The mumps vaccine emerged from Maurice Hilleman's work at Merck, where he isolated the Jeryl Lynn strain from his daughter in 1963 and attenuated it via passages in chick embryo cells, optimizing for safety and efficacy. Licensed in December 1967, it underwent rapid pre-licensure trials showing neutralizing antibody development in over 90% of recipients and low reactogenicity, with strain selection prioritizing minimal neurovirulence in animal models like hamsters. These studies addressed challenges in attenuation by testing multiple passages to eliminate pathogenicity while preserving the virus's ability to induce protective immunity. Rubella vaccine development, also led by Hilleman, utilized the HPV-77 strain further adapted in duck embryo cells to enhance stability and reduce side effects, licensed in 1969 following trials that verified high hemagglutination-inhibiting antibody titers in 90-95% of vaccinees and field efficacy against natural exposure. Strain optimization involved comparative testing of candidates for transmissibility and attenuation, with human challenge models confirming safety in susceptible adults and children. The trivalent MMR combination was formulated by Hilleman in 1971 at Merck, integrating the Edmonston-Enders measles, Jeryl Lynn mumps, and HPV-77/RA 27/3 rubella strains (with the latter refined for better immunogenicity), after trials confirmed no significant antigenic interference, yielding seropositivity rates of 96% for measles, 95% for mumps, and 94% for rubella in over 300 children. Pre-licensure studies emphasized co-administration safety, monitoring for enhanced reactogenicity, and efficacy via parallel antibody assessments, addressing concerns over viral competition through dose adjustments and sequencing evaluations. These efforts culminated in U.S. licensure, marking a shift to simplified immunization schedules.

Licensing, Adoption, and Global Rollout

The combined measles, mumps, and rubella (MMR) vaccine, developed by Merck, received original licensure from the U.S. Food and Drug Administration on April 22, 1971, for prevention of these diseases in individuals 12 months of age and older. This approval followed separate licensures of individual measles (1963), mumps (1967), and rubella (1969) vaccines, enabling the trivalent formulation to streamline administration. In 1977, the Advisory Committee on Immunization Practices (ACIP) recommended routine MMR vaccination for all children at 15 months of age, marking a shift toward combined use to enhance compliance and coverage. The World Health Organization (WHO) incorporated measles vaccination into its Expanded Programme on Immunization (EPI) in 1974, with endorsements for combined measles-rubella and MMR formulations expanding in the 1980s to support integrated delivery in resource-limited settings. By the mid-1980s, global measles vaccination coverage among one-year-olds reached approximately 40%, facilitated by WHO's technical guidance on vaccine strains and scheduling. In the United States, MMR coverage among children aged 24 months rose from under 10% in the early 1970s to over 90% by 2000, driven by school-entry mandates and public health campaigns, though early adoption varied by region due to initial physician hesitancy on combining antigens. Globally, EPI integration propelled MMR rollout, averting an estimated 23.2 million measles deaths from 2000 to 2018 through improved first- and second-dose coverage, which climbed to 86% for the first dose by 2018. Despite these gains, barriers persisted, including the vaccine's cold chain requirements (storage at 2–8°C), which strained infrastructure in low-income countries, and procurement costs, often mitigated through Gavi Alliance subsidies starting in the early 2000s.

Key Events and Policy Shifts

In February 1998, Andrew Wakefield and colleagues published a paper in The Lancet suggesting a potential link between the MMR vaccine and a novel form of autism accompanied by gastrointestinal symptoms, based on a case series of 12 children; this claim, later found to involve data manipulation and ethical violations, triggered widespread public concern. MMR vaccination uptake in the United Kingdom subsequently declined sharply from 92% in 1996 to approximately 80% by 2003, contributing to measles outbreaks, including over 1,300 cases in England and Wales in 2008. The paper was fully retracted by The Lancet in 2010 following investigations revealing fraud, and Wakefield was struck off the UK General Medical Council register that year for serious professional misconduct, including undisclosed financial conflicts and mistreatment of participants. Efforts to eliminate rubella through widespread MMR vaccination in the 1980s and 1990s culminated in the United States Centers for Disease Control and Prevention declaring rubella and congenital rubella syndrome eliminated in the US on March 1, 2004, after no endemic cases were documented since 2000, reflecting vaccination coverage exceeding 90% among school-aged children. Mumps outbreaks in the 2010s, particularly among vaccinated young adults in university settings—such as over 6,000 cases in the US in 2016-2017—highlighted waning immunity despite two-dose MMR schedules, prompting policy shifts toward supplemental dosing. In 2018, the CDC's Advisory Committee on Immunization Practices recommended a third dose of MMR for populations at high risk during outbreaks, supported by studies showing 78-88% effectiveness in outbreak control when administered early. Hesitancy amplified by COVID-19 vaccine debates spilled over to routine immunizations, with US kindergarten MMR coverage falling to 92.7% in the 2023-2024 school year from 93.5% pre-pandemic, alongside exemptions rising to 3.6% by 2024-2025, prompting federal and state initiatives for enhanced outreach, school mandates, and catch-up campaigns to avert resurgence.

Variants

MMRV Combination

The MMRV vaccine integrates the trivalent measles, mumps, and rubella (MMR) components with live attenuated varicella (chickenpox) virus into a single quadrivalent formulation, offering convenience by reducing the number of injections required for immunization against four diseases. ProQuad, produced by Merck & Co., was licensed by the U.S. Food and Drug Administration (FDA) on September 6, 2005, for subcutaneous administration in children aged 12 months to 12 years. It contains the established MMR strains (Enders' Edmonston for measles, Jeryl Lynn for mumps, and Wistar RA 27/3 for rubella) alongside the Oka/Merck strain of varicella-zoster virus, propagated in human diploid cells. Prelicensure clinical trials involving over 5,000 children demonstrated seroconversion rates exceeding 95% for all antigens, with protective antibody responses comparable to those achieved by concomitant separate administration of MMR II and Varivax vaccines. Postlicensure surveillance and comparative studies have confirmed similar overall efficacy against targeted diseases when MMRV is used per schedule, though with elevated reactogenicity. Specifically, the first dose of MMRV is associated with higher rates of fever and injection-site reactions than separate MMR and varicella vaccines given on the same day. A key safety concern is an approximately twofold increased risk of febrile seizures 7–10 days post-vaccination, attributable to the combination effect rather than individual components; cohort studies estimate an excess risk of roughly 1 seizure per 2,300–2,500 first doses in children aged 12–23 months, though these events are typically benign, self-limited, and without long-term neurological sequelae. No increased risk of aseptic meningitis, anaphylaxis, or other serious events has been causally linked beyond baseline vaccine rates. Due to this febrile seizure risk, the Advisory Committee on Immunization Practices (ACIP) has, since 2009, preferred separate MMR and varicella vaccines for the first dose in children aged 12–47 months, recommending MMRV only if parents or caregivers express a strong preference for fewer injections. In September 2025, ACIP voted 8–3 to update guidance, explicitly recommending separate administration for children under 4 years to minimize seizure incidence, while endorsing MMRV for the second dose (aged 4–6 years) or catch-up in older children for logistical benefits. This approach balances immunogenicity equivalence with targeted risk reduction, as MMRV uptake has remained optional rather than routine for initial dosing in U.S. pediatric schedules.

MR Formulations

MR formulations consist of live attenuated vaccines combining measles and rubella virus strains, excluding the mumps component present in MMR vaccines, to target these two diseases in settings where resource constraints limit broader combinations. These dual vaccines prioritize control of measles outbreaks and prevention of congenital rubella syndrome (CRS), which arises from rubella infection during pregnancy and causes severe birth defects. A prominent example is MR-Vac, produced by the Serum Institute of India, which contains not less than 1000 CCID50 of measles virus and sufficient rubella virus antigen per 0.5 mL dose after reconstitution; it is indicated for subcutaneous administration in infants from 9 months of age, children, adolescents, and adults, with recommendations to avoid pregnancy for one month post-vaccination in females of childbearing age due to theoretical risks, though no CRS cases from vaccine transmission have been documented. Seroprotection data from clinical evaluations of Serum Institute's MR vaccine show mean rates of 96.43% for measles and 91.67% for rubella, aligning with broader evidence of single-dose effectiveness exceeding 95% against measles and 90-97% against rubella across age groups in campaign settings.00080-X/fulltext) The World Health Organization (WHO) supports MR vaccines in elimination strategies, recommending their use in two-dose regimens via routine immunization and supplementary campaigns to achieve ≥95% coverage, particularly in regions with ongoing rubella transmission risks. In resource-limited contexts, MR formulations offer advantages such as lower manufacturing costs—due to fewer viral components—and streamlined logistics, including potentially reduced cold-chain demands compared to trivalent options, enabling scalable deployment in high-burden areas like South Asia and sub-Saharan Africa. Their primary limitation is the absence of mumps protection, which may require separate monovalent or combined vaccines if mumps epidemiology warrants it, though this targeted approach allows prioritization of measles-rubella control where mumps incidence is lower or addressed independently.

Public Health Impact

Disease Reduction and Eradication Efforts

Prior to the licensure of the measles vaccine in 1963, the United States experienced an estimated 3 to 4 million measles cases annually, resulting in approximately 48,000 hospitalizations and 400 to 500 deaths each year. Widespread adoption of measles vaccination led to a dramatic decline, with reported cases dropping to fewer than 100 annually in most years from 2000 to 2010. For rubella, endemic transmission was interrupted through vaccination programs, culminating in the elimination of the disease in the United States in 2004, as verified by an independent panel convened by the Centers for Disease Control and Prevention (CDC). Globally, measles vaccination, including through MMR formulations, has averted an estimated 60.3 million deaths between 2000 and 2023, according to World Health Organization (WHO) modeling. The Pan American Health Organization (PAHO) declared the Region of the Americas free of endemic measles transmission in September 2016, marking the first such regional achievement worldwide after sustained high vaccination coverage exceeding 95% in many countries. Efforts toward eradication face ongoing challenges, including the importation of cases via international travel, which accounts for the majority of post-elimination incidents in previously cleared areas. Additionally, an estimated 14.5 million children worldwide received no doses of routine vaccines in 2023, leaving them susceptible to measles and other preventable diseases despite available MMR vaccines. These gaps underscore the need for continued surveillance and coverage improvements to maintain reductions and pursue global interruption of transmission.

Recent Outbreaks and Vaccination Gaps

In the United States, measles cases reached 1,618 confirmed infections as of October 22, 2025, marking the highest annual total since the disease was declared eliminated in 2000. Of these, approximately 87% were linked to outbreaks, primarily among unvaccinated individuals in communities with vaccination coverage below the 95% herd immunity threshold required to prevent sustained transmission. National MMR vaccination coverage among kindergartners fell to 92.5% during the 2024-2025 school year, a decline from prior years, with exemptions rising to 3.6% and over half of states reporting drops in MMR uptake. Modeling studies indicate that such 5% or greater reductions in coverage can predict localized surges, as seen in states like Texas where kindergarten MMR rates dropped to 94.3% by 2024-2025, enabling rapid spread from imported cases. Internationally, the European Region reported over 61,000 measles cases in 2023 across 41 countries, with an estimated 500,000 children missing their first MMR dose that year, contributing to a 30-fold increase from 2022 levels. Cases continued to rise into 2024, exceeding 127,000, driven by gaps in routine immunization amid disruptions from the COVID-19 pandemic and localized hesitancy. In high-coverage settings, breakthrough infections among the two-dose vaccinated occur at rates of 3-5%, typically presenting as mild illness due to the vaccine's 97% effectiveness against severe disease, but outbreaks still disproportionately affect unvaccinated or undervaccinated groups when population immunity dips below 95%. Vaccination gaps in the 2020s stem from vaccine hesitancy—exacerbated by misinformation and eroded trust post-COVID—and barriers to access, including socioeconomic disparities and healthcare disruptions, which have widened immunity shortfalls globally. Empirical data link these factors to resurgences, as measles' high transmissibility (R0 of 12-18) necessitates sustained 95% coverage for herd protection; drops below this, as observed in recent U.S. and European clusters, enable exponential spread from even single importations. Addressing hesitancy through targeted outreach and improving access in underserved areas remains critical to closing these gaps and averting further outbreaks.

Policy Implementation and Exemptions

In the United States, all 50 states and the District of Columbia mandate the MMR vaccine for children entering public schools and childcare facilities, with requirements typically enforced for kindergarten entry following two doses administered at 12-15 months and 4-6 years of age. These policies were widely adopted in the late 1970s, building on earlier measles mandates, as states responded to outbreaks by requiring proof of vaccination or exemptions for school attendance to prevent transmission in congregate settings. Enforcement mechanisms include documentation verification by schools, periodic audits, and exclusion of non-compliant children during outbreaks, with federal support via programs like the Vaccines for Children providing free doses to eligible families. Exemptions fall into medical and non-medical categories, with rationales centered on individual contraindications or protected beliefs. Medical exemptions, granted for conditions like severe allergies to vaccine components or immunosuppression, are permitted in all states and require physician certification; nationally, they account for approximately 0.2-0.5% of kindergarteners, far lower than non-medical rates. Non-medical exemptions—religious in 45 states plus DC and philosophical/personal belief in 15 states—allow opt-outs based on sincerely held convictions, though processes vary, with some states imposing counseling or annual renewals. Total exemption rates have risen to 3.6% among kindergartners in the 2024-2025 school year, concentrated in clusters that correlate with heightened outbreak risk, as evidenced by the 2019 U.S. measles resurgence (1,282 cases), where over 70% of cases occurred in unvaccinated individuals from communities with high religious exemptions in New York and California. Internationally, MMR policy implementation differs, often tying vaccination to social benefits or eliminating non-medical exemptions to enforce herd immunity thresholds. Australia's "No Jab, No Pay" policy, enacted federally in 2016, withholds family tax benefits and childcare subsidies from parents of under-vaccinated children unless medical exemptions apply, resulting in a 1-3% increase in timely MMR coverage and substantial catch-up vaccinations, particularly in lower socioeconomic areas. Similar incentive-based approaches appear in parts of Europe, while countries like France and Italy, post-2017-2018 outbreaks, expanded mandatory MMR requirements to 10-11 childhood vaccines and restricted non-medical exemptions, boosting coverage above 95% in targeted regions. These measures reflect empirical prioritization of population-level compliance over individual opt-outs where data indicate exemptions undermine outbreak control.

References

  1. [1]
    History of measles vaccination - World Health Organization (WHO)
    In 1971 Hilleman combined the recently developed vaccines against measles, mumps and rubella into the MMR vaccine, administered as a single shot, with one ...Missing: definition composition
  2. [2]
    MMR Vaccine - StatPearls - NCBI Bookshelf
    May 5, 2025 · The measles-mumps-rubella (MMR) vaccine effectively prevents measles by stimulating the immune system to produce antibodies against the live-attenuated virus.Missing: composition date
  3. [3]
    Measles, Mumps and Rubella (MMR): The Diseases & Vaccines
    Jun 26, 2025 · Vaccines to prevent each of these diseases were first developed in the 1960s. The three vaccines were combined to form the MMR vaccine in 1971.Missing: composition date
  4. [4]
    Cochrane Review confirms effectiveness of MMR vaccines
    Apr 17, 2020 · After one dose of vaccine was 89% effective in preventing rubella, and one study found that after 10 years the MMRV vaccine was 95% effective at ...
  5. [5]
    The effectiveness of measles-mumps-rubella (MMR) vaccination in ...
    MMR vaccination is effective for the primary prevention of target and not targeted infectious diseases and may also limit hospitalizations for respiratory ...
  6. [6]
    Measles, Mumps and Rubella - Institute for Vaccine Safety
    Oct 7, 2025 · Rare adverse events from MMR vaccine include thrombocytopenia, parotitis, lymphadenopathy and encephalopathy. Very rare adverse events from MMR ...
  7. [7]
    Vaccines for measles, mumps, rubella, and varicella in children
    Nov 22, 2021 · However, some people think the MMR vaccine causes unwanted effects such as autism, swelling of the brain (encephalitis), meningitis, learning ...<|separator|>
  8. [8]
    The MMR vaccine and autism: Sensation, refutation, retraction ... - NIH
    In 1998, Andrew Wakefield and 12 of his colleagues[1] published a case series in the Lancet, which suggested that the measles, mumps, and rubella (MMR) ...
  9. [9]
    Lancet retracts 12-year-old article linking autism to MMR vaccines
    Feb 2, 2025 · Twelve years after publishing a landmark study that turned tens of thousands of parents around the world against the measles, mumps and rubella (MMR) vaccineMissing: controversies | Show results with:controversies
  10. [10]
    Quantifying the effect of Wakefield et al. (1998) on skepticism about ...
    Aug 19, 2021 · Vaccine skepticism increased following the publication of AW98, which was potentially made possible by increased negative media coverage of MMR.
  11. [11]
    [PDF] MMR II - Merck.com
    These products may contain antibodies that interfere with vaccine virus replication and decrease the expected immune response.
  12. [12]
    Seroconversion rates following 2 doses of measles- mumps - NIH
    Jan 16, 2022 · After MMR1 vaccination from 52 seronegative children, 80.7%, 78.8% and 75% were seroconverted. These rates increased to 94.8%, 89.7% and 94.8% ...
  13. [13]
    MMR vaccine - how effective and how safe?
    Seroconversion rates after the first dose of MMR vaccine are around 88-100% for measles, mumps and rubella, similar to rates with single-antigen vaccines ...<|control11|><|separator|>
  14. [14]
    Human Cell Strains in Vaccine Development - HistoryOfVaccines.org
    The WI-38 cell strain was developed in 1962 in the United States, and the MRC-5 cell strain (also started with fetal lung cells) was developed, using Hayflick's ...
  15. [15]
    News & Views: Why Were Fetal Cells Used to Make Certain Vaccines?
    Apr 24, 2017 · This second cell line was named MRC-5. Ultimately, the rubella vaccine and one rabies vaccine were made using WI-38 cells, but due to concerns ...
  16. [16]
    Vaccine Manufacturing - PMC - PubMed Central - NIH
    The vaccine is reconstituted just before use. Other manufacturers use different cell substrates; for example, the Serum Institute of India uses human diploid ...Table 5.1 · Examples Of Vaccine... · Industry's Response To New...
  17. [17]
    Everything You Need To Know About The MMR Vaccine
    ... WI-38 human diploid lung fibroblasts. The cells, virus pools, recombinant human serum albumin and fetal bovine serum used in manufacturing are tested and ...
  18. [18]
    Frequently asked questions about MMR ® II - Merck Vaccines
    M-M-R®II Vaccine Active Ingredients: weakened forms of the measles, mumps, and rubella viruses. M-M-R®II Vaccine Inactive Ingredients: sorbitol, sucrose, ...
  19. [19]
    [PDF] Package Insert - PRIORIX - FDA
    PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. 2. DOSAGE ...
  20. [20]
    Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of
    Nov 18, 2022 · PRIORIX is formulated without preservatives and is administered as subcutaneous injection (the same as M-M-R II) (5,29). PRIORIX may be used ...Missing: stabilizers | Show results with:stabilizers
  21. [21]
    Vaccine manufacturing - PMC - PubMed Central - NIH
    QC testing at this stage also consists of safety, potency, purity, sterility, and other assays that may be specific to the product. Vaccine efficacy can be ...
  22. [22]
    Assessment | WHO - Prequalification of Medical Products (IVDs ...
    The samples subject to testing must comply in all respects with the information and specifications stated in the Vaccines Prequalification Dossier (VPQD).
  23. [23]
    [PDF] quality control of who prequalified vaccines - Paho.org
    24. CONCLUSION. • NCL testing of prequalified vaccines requires: • Skilled staff & appropriate facilities. • QA system in place for vaccine testing (lot release).
  24. [24]
    Immunogenicity and safety of measles-mumps-rubella vaccine ... - NIH
    We conducted a randomized, non-inferiority, clinical study of MMR vaccine by a disposable-syringe jet injector (DSJI) in toddlers in India in comparison with ...
  25. [25]
    Measles: Background, Pathophysiology, Etiology
    Jun 3, 2025 · The cause of measles is the measles virus, a single-stranded, negative-sense enveloped RNA virus of the genus Morbillivirus within the family ...
  26. [26]
    Measles - StatPearls - NCBI Bookshelf
    May 5, 2025 · The measles virus has no animal reservoir and occurs only in humans. The virus is highly contagious, with each case capable of causing 14 to 18 ...Measles · Epidemiology · Pathophysiology
  27. [27]
    The basic reproduction number (R0) of measles: a systematic review
    R 0 is often cited to be 12–18, which means that each person with measles would, on average, infect 12–18 other people in a totally susceptible population.
  28. [28]
    Clinical Overview of Measles - CDC
    1 out of every 1,000 measles cases will develop acute encephalitis, which often results in permanent brain damage. · 1 to 3 out of every 1,000 children who ...Stay Alert for Measles Cases · Clinical Diagnosis Fact Sheet
  29. [29]
    Measles Symptoms and Complications - CDC
    May 9, 2024 · About 1 child out of every 1,000 who get measles will develop encephalitis (swelling of the brain). This can lead to convulsions and leave the ...
  30. [30]
    Measles Infection and Encephalitis
    1-3 in 1,000 children contracting measles will develop encephalitis concurrent with the measles infection, called primary measles encephalitis. · 1 in 1,000 ...
  31. [31]
    Chapter 13: Measles | Pink Book - CDC
    Apr 24, 2024 · Measles Secular Trends in the United States. About 500,000 reported cases and 500 deaths annually before vaccine. Actual cases estimated at 3 ...
  32. [32]
    Measles - PAHO/WHO | Pan American Health Organization
    Before widespread vaccination began in 1980, measles caused 2.6 million deaths a year throughout the world, 12,000 of them in the Americas. Between 1970 and ...
  33. [33]
    Subacute sclerosing panencephalitis as a re-emerging condition ...
    Jun 7, 2025 · The incidence, according to US data, is 4–11 per 100,000 cases of measles [5, 9]. Children under one year have a measles rate 18 times higher ...
  34. [34]
    Subacute Sclerosing Panencephalitis: Recent Advances in... - LWW
    There are an estimated 18 cases of SSPE per 100,000 measles cases among children who contract measles early in life. Furthermore, lower- and middle-income ...
  35. [35]
    Paramyxoviruses - Medical Microbiology - NCBI Bookshelf - NIH
    Clinical Manifestations. Mumps is a systemic febrile infection of children and young adults. Swelling of the salivary glands, especially the parotid glands, is ...Missing: R0 | Show results with:R0
  36. [36]
    Clinical Overview of Mumps - CDC
    Jan 17, 2025 · Common clinical features include parotitis (swollen salivary glands in cheek and jaw area) and fever. Mumps spreads through direct contact with ...Missing: R0 | Show results with:R0
  37. [37]
    Mumps - StatPearls - NCBI Bookshelf
    May 1, 2024 · Common complications of mumps include orchitis, oophoritis, mastitis, pancreatitis, encephalitis, and aseptic meningitis. The combination ...Missing: R0 | Show results with:R0
  38. [38]
    Mumps orchitis - PMC - NIH
    Mumps orchitis rarely leads to sterility but it may contribute to subfertility. It can also can lead to oligospermia, azoospermia, and asthenospermia (defects ...
  39. [39]
    the possible pathogenesis and incidence of deafness - PubMed
    The incidence of deafness following mumps appears to be extremely low, approximately 1:20,000, as estimated by Everberg (1957). MeSH terms. Adolescent; Adult ...Missing: encephalitis rates
  40. [40]
    Chapter 15: Mumps | Pink Book - CDC
    May 1, 2024 · Mumps became nationally notifiable in 1968 with about 152,000 cases reported. After the use of the mumps vaccine, cases began to decrease ...
  41. [41]
    History of mumps: Outbreaks and vaccine timeline - Mayo Clinic
    About 162,000 cases of mumps occurred each year in the U.S. in the 20th century compared with 429 in 2023. 1971. The measles, mumps and rubella vaccines are ...
  42. [42]
    Current Status of Mumps Virus Infection: Epidemiology ...
    However, in 2016 and 2017, the number of cases of mumps increased almost two-times compared to those reported in the previous five years in the United States ( ...
  43. [43]
    Chapter 20: Rubella | Pink Book - CDC
    Apr 25, 2024 · Congenital infection with rubella virus can affect many organ systems. Congenital rubella syndrome includes a constellation of birth defects, ...
  44. [44]
    Clinical Overview of Rubella - CDC
    Jul 15, 2024 · Rubella is characterized by a mild, maculopapular rash along with lymphadenopathy, and a slight fever. About 25% to 50% of infections are asymptomatic.
  45. [45]
    About Rubella - CDC
    Signs and symptoms · Low-grade fever · Sore throat · A rash that starts on the face and spreads to the rest of the body.Missing: characteristics | Show results with:characteristics
  46. [46]
    Rubella - Symptoms & causes - Mayo Clinic
    Sep 20, 2025 · Congenital rubella syndrome occurs in up to 85% of infants ... The highest risk to the fetus is during the first three months of pregnancy.Overview · Prevention · Do I Need The Mmr Vaccine?
  47. [47]
    Congenital Rubella Syndrome (CRS) | Texas DSHS
    Women showing rubella symptoms during their first 12 weeks (first trimester), are at risk for CRS congenital defects. This occurs in up to 85% of infants ...Congenital Rubella Syndrome... · Organism · General Information And...<|separator|>
  48. [48]
    Congenital Rubella - StatPearls - NCBI Bookshelf - NIH
    If infection happens before 18 weeks gestation, the fetus is at high risk for infection and severe symptoms. Termination of pregnancy could be discussed based ...
  49. [49]
    Rubella - StatPearls - NCBI Bookshelf
    Jul 7, 2025 · [4]. Go to: History and Physical. Postnatal rubella infection can be asymptomatic in approximately 25% to 50% of cases. ... Rubella transmission ...
  50. [50]
    Impact of U.S. MMR Vaccination Program | Rubella - CDC
    Jan 17, 2025 · Learn more about CRS. During the last major rubella epidemic in the United States from 1964 to 1965, an estimated: 12.5 million people got ...
  51. [51]
    Rubella - Immunization, Vaccines and Biologicals
    WHO recommends that all countries that have not yet introduced rubella vaccine, and are providing two doses of measles vaccine using routine immunization and/or ...
  52. [52]
    Assessing herd immunity against rubella in Japan
    Jan 27, 2016 · The herd immunity threshold against rubella was calculated by 1−(1/R0), and came to 83.6%.
  53. [53]
    Immune Response Rates for M-M-R®II (Measles, Mumps, and ...
    In a clinical trial of 284a patients, M-M-R®II seroconversion rates were high after the first dose. ... In these studies, a single injection of the vaccine ...
  54. [54]
    A systematic review and modelling insights of factors impacting ...
    Aug 28, 2025 · A retrospective cohort study in Spain (N = 1394), during a measles outbreak, found that the MMR vaccine had a 96% effectiveness (95% CI: 89–98% ...
  55. [55]
    Long-term Immunogenicity of Measles Vaccine - Oxford Academic
    According to postlicensure data, 1 dose of measles-mumps-rubella (MMR) vaccine is 93% effective and receipt of 2 doses is 97% effective against measles [2].
  56. [56]
    Two-dose measles vaccine effectiveness remains high over time
    Sep 7, 2023 · Our study confirms the continued high effectiveness of two doses of MCV with only slight degradation, decades after immunization.Missing: real- | Show results with:real-
  57. [57]
    Early reports show mumps on the rise in 2016, including on campuses
    Apr 8, 2016 · One dose of the MMR vaccine affords 78% protection, while two doses provide 88% effectiveness, according to the CDC. The vaccine is the best ...
  58. [58]
    Mumps Outbreak at a University and Recommendation for a Third ...
    Jul 29, 2016 · 89% of patients with mumps had received at least 2 doses of measles-mumps-rubella (MMR) vaccine, and a third dose was recommended as a control measure.
  59. [59]
    Mumps Outbreaks at Four Universities — Indiana, 2016 | MMWR
    Jul 27, 2018 · Seven vaccination clinics were held across three schools, and 5,273 doses of MMR were administered, most (3,106; 59%) at highly attended clinics ...Missing: colleges | Show results with:colleges
  60. [60]
    Patterns of Decline in Measles, Mumps, and Rubella Neutralizing ...
    Apr 9, 2025 · Neutralizing antibody levels against measles, mumps, and rubella (MMR) declined over 10 years in 2- and 3-dose MMR vaccinees.
  61. [61]
    Resurgence of Mumps in Korea - PMC - NIH
    Genotype mismatch between the vaccine strain and wild-type mumps virus strains can reduce the protection against outbreak mumps strains [47]. Mumps viruses are ...
  62. [62]
    Cross-neutralization between vaccine and circulating wild-type ...
    Mar 26, 2021 · The aim of this study was to investigate whether the Jeryl Lynn vaccine has low cross-neutralization titers against wild-type MuV.
  63. [63]
    Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak ...
    Sep 7, 2017 · Students who had received a third dose of MMR vaccine had a lower risk of mumps than did those who had received two doses, after adjustment for the number of ...
  64. [64]
    The effect of time since measles vaccination and age at first dose on ...
    In elimination settings, two-dose VE estimates increased as age at first dose of MCV increased and decreased as time since MCV increased; however, the small ...
  65. [65]
    About MMR and MMRV Vaccines: For Providers - CDC
    Learn about the MMR and MMRV vaccine composition and dosage. Both vaccines contain live, attenuated measles, mumps, and rubella virus.Missing: history introduction developer
  66. [66]
    Quantification of Waning Immunity After Measles Vaccination ...
    Aug 4, 2023 · The average rate of waning immunity against measles after the first dose of measles, mumps, and rubella (MMR) vaccine (ages 1.5-10 years) was 9.7% per year.
  67. [67]
    Long-term waning of vaccine-induced immunity to measles in England
    Sep 26, 2024 · We aimed to evaluate whether measles dynamics observed in England between 2010 and 2019 were in line with a waning of vaccine-induced immunity.
  68. [68]
    Routine MMR Vaccination Recommendations: For Providers - CDC
    CDC recommends two doses of measles-containing vaccine routinely for children, starting with the first dose at age 12 through 15 months and the second dose at ...
  69. [69]
    Measles Vaccination - CDC
    Jan 17, 2025 · MMR & MMRV vaccines usually protect people for life against measles and rubella; but immunity against mumps may decrease over time. Smiling ...Plan for Travel · Reasons to Follow CDC's · Possible Side Effects
  70. [70]
    MMR Vaccine: When Is the Right Time for the Second Dose? - PMC
    With the growing body of evidence, the ACIP recommended that the scheduled dose of measles vaccine be changed to 15 months.
  71. [71]
    [PDF] Measles vaccine recommendations for non-pregnant adults aged 19 ...
    If vaccination history** not known, or has received no doses, should receive. 2 doses of MMR vaccine ≥28 days apart. If person has received one dose, administer.<|separator|>
  72. [72]
    Measles - World Health Organization (WHO)
    Nov 14, 2024 · An estimated 107 500 people died from measles in 2023 – mostly children under the age of five years, despite the availability of a safe and cost ...
  73. [73]
    Vaccination schedule for Measles - WHO Immunization Data portal
    4) One MMR dose for women of childbearing age only vaccinated once. 5) Mothers with a seronegative rubella test in pregnancy should be given 2 MMR doses ...
  74. [74]
    Contraindications and Precautions | Vaccines & Immunizations - CDC
    Jul 25, 2024 · A vaccine should not be administered when a contraindication is present; for example, MMR vaccine should not be administered to severely immunocompromised ...Key Points · Updates · Precautions
  75. [75]
    [PDF] Package Insert - Measles, Mumps, and Rubella Virus Vaccine Live
    M-M-R II vaccine contains live attenuated measles, mumps and rubella viruses. M-M-R II vaccine is contraindicated for use in pregnant women because ...Missing: sources | Show results with:sources
  76. [76]
    Measles Vaccination Recommendations - MN Dept. of Health
    Jul 16, 2025 · Pregnancy should be avoided for 28 days following MMR vaccine. Severe allergic reaction (anaphylactic)to a previous dose of a vaccine component.Vaccine Recommendations · Mmr Vaccine... · Contraindications
  77. [77]
    Anaphylaxis to measles, mumps, and rubella vaccine mediated by ...
    The vaccine contains neomycin, which is unlikely to cause anaphylaxis and to which our patient has a negative skin test. ** The primary components of the ...
  78. [78]
    Anaphylaxis to measles, mumps, and rubella vaccine mediated by ...
    We conclude that the patient has an anaphylactic sensitivity to gelatin, and that her anaphylaxis to MMR vaccine was caused by the gelatin component.
  79. [79]
    Recommendations for using MMR vaccine in children allergic to eggs
    This study found that five allergic reactions occurred during the administration of 2789 doses of MMR vaccine, although two children had had other vaccinations ...
  80. [80]
    Egg allergy and MMR vaccine: New recommendations from ... - NIH
    These studies have reported uneventful routine MMR immunization in egg-allergic individuals (8–11) and in those with positive MMR skin tests (12).
  81. [81]
    Safety of measles, mumps, and rubella vaccine in egg allergy
    Nov 15, 2020 · In this study, we describe a thorough allergy workup aimed at demonstrating in real-life that there is no association between egg allergy and ...
  82. [82]
    Safety and immunogenicity of the measles-mumps-rubella vaccine ...
    Jun 20, 2025 · The seroconversion rates after a single MMR vaccination were 75 % (3/4) for IBD and 72.7 % (8/11) after LT. Table 2. Vaccination response to ...<|separator|>
  83. [83]
    Adverse Events Following Measles, Mumps, and Rubella Vaccine in ...
    MMR is well tolerated, and most adverse events (AEs) are mild and self-limited (eg, fever, rash, lymphadenopathy, parotitis, transient arthralgias/arthritis).
  84. [84]
    Ask the Experts: MMR (Measles, Mumps, and Rubella) - Immunize.org
    Sep 3, 2025 · Read answers by medical experts to healthcare provider questions on vaccines and MMR (Measles, Mumps, and Rubella).Missing: strains sources
  85. [85]
    [PDF] MEASLES, MUMPS AND RUBELLA VACCINES
    The risk for thrombocytopenia following MMR vaccination may be increased for those with a previous diagnosis of immune thrombocytopenic purpura, especially for ...
  86. [86]
    Prevention of measles, mumps and rubella: 40 years of global ... - NIH
    Effectiveness of M-M-RII in outbreak settings. Real-world observational studies have confirmed that M-M-RII is highly effective in outbreak settings in ...
  87. [87]
    Measles, Mumps, Rubella (MMR) Vaccine Safety - CDC
    Jul 31, 2024 · The FDA approved M-M-R II in 1971 for use in people 12 months of age and older. The FDA approved PRIORIX in 2022 for use in people 12 months of ...
  88. [88]
    Delayed onset rash and fever after MMR vaccination
    May 23, 2025 · Delayed onset rashes and fevers occurred in 2 to 5% of children in a clinical trial of 752 children, age 12 months through 18 months of age, who ...
  89. [89]
    Table. Comparison of the effects of diseases and the side effects of ...
    Jan 18, 2025 · About 1 in 20 develops a rash, which is non-infectious. Low platelet count (causing bruising or bleeding) occurs after the 1st dose of MMR ...
  90. [90]
    VAERS - Data - HHS.gov
    May 8, 2025 · Vaccine providers are encouraged to report any clinically significant health problem following vaccination to VAERS even if they are not sure if ...Guide to Interpreting VAERS... · Data Sets · Resources
  91. [91]
    Wakefield's article linking MMR vaccine and autism was fraudulent
    Jan 6, 2011 · The 1998 Lancet paper that implied a link between the measles, mumps, and rubella (MMR) vaccine and a “new syndrome” of autism and bowel disease.Missing: GMC | Show results with:GMC
  92. [92]
    Measles, Mumps, Rubella Vaccination and Autism - ACP Journals
    The study strongly supports that MMR vaccination does not increase the risk for autism, does not trigger autism in susceptible children, and is not associated ...
  93. [93]
    A Population-Based Study of Measles, Mumps, and Rubella ...
    This study provides strong evidence against the hypothesis that MMR vaccination causes autism. It has been suggested that the measles, mumps, and rubella (MMR) ...Missing: parotitis | Show results with:parotitis
  94. [94]
    Vaccines are not associated with autism: an evidence-based meta ...
    Jun 17, 2014 · There has been enormous debate regarding the possibility of a link between childhood vaccinations and the subsequent development of autism.
  95. [95]
    Vaccines and Autism: A Tale of Shifting Hypotheses - Oxford Academic
    Abstract. Although child vaccination rates remain high, some parental concern persists that vaccines might cause autism. Three specific hypotheses have bee.
  96. [96]
    Vaccines and Autism: A Tale of Shifting Hypotheses - PMC
    Although child vaccination rates remain high, some parental concern persists that vaccines might cause autism. Three specific hypotheses have been proposed.
  97. [97]
    Removing Thimerosal from Vaccines Did Not Reduce Autism Case...
    a mercury-containing preservative — from most pediatric vaccines, the number of autism cases in California ...
  98. [98]
    Vaccines and Autism | Children's Hospital of Philadelphia
    Sep 27, 2025 · Two studies have been cited by those claiming that the MMR vaccine causes autism. Both studies are critically flawed.
  99. [99]
    Assessment of Citations of the Retracted Article by Wakefield et al
    Nov 15, 2019 · ... Wakefield et al that purported to show an association between the measles-mumps-rubella (MMR) vaccine and autism. The article was retracted ...
  100. [100]
    Family to Receive $1.5M+ in First-Ever Vaccine-Autism Court Award
    Sep 10, 2010 · In acknowledging Hannah's injuries, the government said vaccines aggravated an unknown mitochondrial disorder Hannah had which didn't "cause ...
  101. [101]
    Vaccines and Autism Revisited — The Hannah Poling Case
    May 15, 2008 · ... Hannah was diagnosed with encephalopathy caused by a mitochondrial enzyme deficit. ... vaccine-preventable diseases. These diseases aren't merely ...
  102. [102]
    Acute Encephalopathy Followed by Permanent Brain Injury or Death ...
    Their review identified no conclusive evidence of the occurrence of encephalopathy or encephalitis after the administration of measles or mumps vaccine.
  103. [103]
    Measles Cases and Outbreaks - CDC
    There have been 3 confirmed deaths from measles. Note: The total number of cases includes cases among international visitors to the U.S. ...History of Measles · Be Ready for Measles Toolkit · Measles Resources · Ncird
  104. [104]
    The Effects of Vaccination Status and Age on Clinical Characteristics ...
    Sep 13, 2024 · According to the U.S. measles vaccination schedule, a first dose is recommended from 12–15 months of age and a second dose from 4–6 years of age ...
  105. [105]
    [PDF] Breakthrough Measles Infections Chicago, March-April 2024
    Sep 10, 2024 · • 2 doses of MMR vaccine are 97% effective at preventing measles and 1 dose is 93% effective1. • 19 out of 67 measles cases were breakthrough.Missing: two- | Show results with:two-
  106. [106]
    Mumps outbreaks across England - GOV.UK
    Feb 14, 2020 · The rise in cases looks set to continue in 2020, with 546 confirmed cases in January 2020 compared to 191 during the same period in 2019. The ...Missing: populations | Show results with:populations
  107. [107]
    Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic ...
    Persons with mumps are infectious from 2 days before through 5 days after parotitis onset, and transmission is through respiratory droplets. Despite the success ...
  108. [108]
    Mumps Cases and Outbreaks - CDC
    Sep 12, 2025 · U.S. mumps cases decreased significantly after the mumps vaccine program began in 1967, but they have increased since 2006. Most recent ...
  109. [109]
    Mumps in Vaccinated Children and Adolescents: 2007–2019
    Aug 6, 2025 · A median of 87% (range: 81%–94%) of pediatric patients each year had previously received ≥1 measles, mumps, and rubella (MMR) vaccine dose.
  110. [110]
    Study: MMR Vaccine Protection Wanes Slightly Over Time
    Oct 25, 2024 · The researchers noted that this waning of vaccine-induced immunity could worsen outbreaks primarily related to decreases in vaccine coverage.
  111. [111]
    Long-term immunogenicity after measles vaccine vs. wild infection
    The seroconversion rate after two doses of MMR vaccine in the disease group was 100% (95%CI = 59–100%), while in the vaccinated group it was 86% (95%CI = 73–94 ...Missing: strains | Show results with:strains
  112. [112]
    Onward Virus Transmission after Measles Secondary Vaccination ...
    Aug 9, 2024 · Our findings suggest that the risk for onward transmission from persons with measles SVF is very low but not zero. In large outbreak situations ...
  113. [113]
    Mumps Outbreaks in Vaccinated Populations—Is It Time to Re ...
    This review aims to discuss in detail the interplay of factors thought to be contributing to the current mumps outbreaks seen in highly vaccinated populations.
  114. [114]
    Exacerbation of measles mortality by vaccine hesitancy worldwide
    Measles is highly transmissible, requiring coverage of at least 95% to maintain herd immunity.
  115. [115]
    How Herd Immunity Works | History of Vaccines
    Feb 22, 2025 · To calculate the herd immunity threshold, scientists use the formula: 1 – (1/R₀). For measles (R₀=15), this means 1 – (1/15) = 1 - 0.067 = 0. ...
  116. [116]
    The 2019 U.S. Measles outbreaks: A public health crisis
    This is precisely what occurred this year – 89% of the measles cases in 2019 were in individuals who were unvaccinated or had unknown vaccine status. Sadly ...
  117. [117]
    National Update on Measles Cases and Outbreaks — United States, ...
    Oct 11, 2019 · The combination of maintenance of high national vaccination coverage with measles, mumps, and rubella vaccine (MMR) and rapid implementation of ...
  118. [118]
    What causes breakthrough measles infections? - NBC News
    Apr 20, 2025 · Research suggests that when breakthrough infections occur, the MMR vaccine still tends to provide some partial protection.
  119. [119]
    Breakthrough Infections: A Challenge towards Measles Elimination?
    Aug 4, 2022 · Primary vaccination failure has been observed in around 5% (range 2–7%) [51] of measles vaccinees and for this reason two doses of measles ...
  120. [120]
    What's going on with measles? | Journal of Virology
    Jul 23, 2024 · Measles induces lifelong immunity to reinfection but loss of immunity to other pathogens. An attenuated live virus vaccine is highly effective, ...
  121. [121]
    Comparative Analysis of Long-Term Measles Immune Response ...
    While antibodies induced by vaccination waned faster than those from natural infection in our study, vaccination still provided durable and effective protection ...
  122. [122]
    The Case against compulsory vaccination - Journal of Medical Ethics
    Arguments for mandatory or compulsory vaccination must justify the coercive infringement of bodily integrity via the injection of chemicals that permanently ...
  123. [123]
    Civil Liberties and Vaccine Mandates: Here's Our Take | ACLU
    Sep 2, 2021 · Vaccines are a justifiable intrusion on autonomy and bodily integrity. That may sound ominous, because we all have the fundamental right to ...
  124. [124]
    Eliminating nonmedical exemptions: a radical shift in how childhood ...
    Jul 11, 2023 · Some state vaccination laws contribute to greater exemption rates and disease outbreaks in the United States. Health Affairs. 2015;34(8): ...Missing: fatigue | Show results with:fatigue
  125. [125]
    Pandemic paradox: How the COVID-19 crisis transformed vaccine ...
    Aug 12, 2025 · The distrust fostered during the COVID-19 pandemic has extended to routine childhood immunizations, raising the alarming possibility of ...
  126. [126]
    Research Suggests Link Between COVID-19 Vaccine Hesitancy and ...
    Jan 31, 2025 · “Our research suggests that COVID-19 vaccine hesitancy has fueled increasing MMR vaccine hesitancy, leaving children more vulnerable to highly ...
  127. [127]
    Decline in Vaccination Coverage by Age 24 Months and ... - CDC
    Sep 26, 2024 · A recent analysis of trends in parental vaccine hesitancy during 2019–2022 found an increase in hesitancy among parents of children aged 5–11 ...
  128. [128]
    John F. Enders and measles virus vaccine--a reminiscence - PubMed
    John E Enders conducted the research, development, and initial clinical studies responsible for the licensure in 1963 of a successful live attenuated measles ...
  129. [129]
    History of Measles - CDC
    May 9, 2024 · In the first decade of reporting, an average of 6,000 measles-related deaths were reported each year. A vaccine became available in 1963. In the ...
  130. [130]
    The First Measles Vaccine | American Academy of Pediatrics
    Sep 1, 2011 · The development of the first successful live attenuated vaccine against measles began in the laboratory of John Enders.
  131. [131]
    Celebrating 50 Years of the Mumps Vaccine - NFID
    Hilleman started down the path of creating the vaccine using mumps virus that he isolated from his daughter, Jeryl Lynn (the older girl to the left in the photo) ...
  132. [132]
    Mumps | History of Vaccines
    In the United States, cases of mumps have dropped by 99% since the introduction of a vaccine in 1967. Unlike measles and rubella, however, mumps has not yet ...
  133. [133]
    Maurice Hilleman - PMC - NIH
    Maurice Hilleman was responsible for developing more than 40 vaccines, including measles, mumps, hepatitis A, hepatitis B, meningitis, pneumonia, Haemophilus ...
  134. [134]
    Rubella (German Measles) | History of Vaccines
    During that short period, there were 12.5 million cases of rubella. Twenty thousand children were born with CRS: 11,000 were deaf, 3,500 blind, and 1,800 ...
  135. [135]
    Measles, Mumps, and Rubella Vaccines | Smithsonian Institution
    One of the standard childhood vaccinations in the United States is the MMR vaccine, which produces immunity against measles, mumps, and rubella.Missing: composition | Show results with:composition
  136. [136]
    Trivalent Combined Measles-Mumps-Rubella Vaccine
    Overall, 96% of the children developed measles hemagglutination-inhibiting, 95% developed mumps neutralizing, and 94% developed rubella hemagglutination- ...
  137. [137]
    Purple Book Database of Licensed Biological Products
    Proper Name: Measles, Mumps and Rubella Virus Vaccine. Live BLA Number: 101069. Applicant: Merck Sharp & Dohme LLC. Original Approval Date: April 22, 1971.
  138. [138]
    Recommendation of the Advisory Committee on Immunization ...
    Jan 12, 2018 · In 1977, ACIP recommended 1 dose of mumps vaccine for all children aged ≥12 months (4). In response to multiple measles outbreaks in the late ...
  139. [139]
    Measles Eradication: Recommendations from a Meeting ... - CDC
    In 1974, only 5% of the world's children aged 12-23 months had been vaccinated against measles. By the mid-1980s, measles vaccination coverage among ...<|separator|>
  140. [140]
    Measles, Mumps, and Rubella -- Vaccine Use and Strategies ... - CDC
    Two doses of MMR vaccine separated by at least 1 month (i.e., a minimum of 28 days) and administered on or after the first birthday are recommended for all ...
  141. [141]
    Progress Toward Regional Measles Elimination — Worldwide, 2000 ...
    Dec 6, 2019 · During 2000–2018, measles vaccination averted an estimated 23.2 million deaths. However, the number of measles cases in 2018 increased 167% ...Missing: rollout EPI
  142. [142]
    Left out in the cold - inequity in infectious disease control due to cold ...
    Jan 25, 2025 · For rural areas in low and middle income countries, there is an increased risk of disruption to cold chain management during transportation. One ...
  143. [143]
    Impact of Vaccines; Health, Economic and Social Perspectives
    Central to this is limited financial resources, but other barriers to vaccine introduction include: underappreciation of the value of vaccines locally/ ...
  144. [144]
    MMR - Vaccinating Britain - NCBI Bookshelf - NIH
    Vaccination rates continued to drop, and measles cases were on the rise, including an outbreak in London. The drip of newspaper articles questioning MMR became ...Vaccination policy in the 1980s · The MMR crisis · Declining confidence
  145. [145]
    Wakefield is struck off for the “serious and wide-ranging findings ...
    May 24, 2010 · Andrew Wakefield, the British gastroenterologist who sparked a worldwide scare over the measles, mumps, and rubella (MMR) vaccine, has been found guilty of ...Missing: timeline | Show results with:timeline
  146. [146]
    Elimination of Rubella From the United States - AAP Publications
    Mar 1, 2006 · The national objective of elimination of rubella and CRS by 2010 from the United States has been attained. ... eradication of rubella at a future ...
  147. [147]
    Rubella - UpToDate
    In 2004, rubella was officially declared eliminated from the United States [2]; in 2015, rubella was eliminated from the ...
  148. [148]
    Coverage with Selected Vaccines and Exemption Rates Among ...
    Oct 17, 2024 · Coverage dropped below 93% for the 2023–24 school year, ranging from 92.3% for DTaP to 92.7% for MMR. Exemptions increased to 3.3%, compared with those during ...
  149. [149]
    Vaccination Coverage and Exemptions among Kindergartners - CDC
    Jul 31, 2025 · During the 2024-2025 school year, exemptions from one or more vaccines among kindergartners in the U.S. increased to 3.6% from 3.3% the year ...
  150. [150]
    MMR vaccination coverage in the U.S. before and after the COVID ...
    Feb 14, 2025 · Various factors have been shown to impact childhood vaccination rates in the U.S, including parental vaccine hesitancy, socioeconomic ...
  151. [151]
    Licensure of a Combined Live Attenuated Measles, Mumps, Rubella ...
    Dec 2, 2005 · On September 6, 2005, the Food and Drug Administration licensed a combined live attenuated measles, mumps, rubella, and varicella (MMRV) ...Missing: FDA | Show results with:FDA
  152. [152]
    About the Varicella Vaccine - CDC
    ProQuad® is a combination measles, mumps, rubella, and ... Both vaccines contain live, attenuated varicella-zoster virus derived from the Oka strain.
  153. [153]
    [PDF] ProQuad - FDA
    ProQuad®. Measles, Mumps, Rubella and Varicella Virus Vaccine Live. Suspension for intramuscular or subcutaneous injection. Initial U.S. Approval: 2005.
  154. [154]
    Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Safety - CDC
    Jul 31, 2024 · The rates of febrile seizures that occurred 7-10 days after vaccination were 8.5 per 10,000 in the MMRV vaccine group compared with 4.2 per 10, ...Previous Studies · Vsd Mmrv Safety Study · Vsd Mmrv Vaccine Safety...
  155. [155]
    Experts no longer prefer MMRV over separate shots
    A CDC post-licensure MMRV safety study found that the rate of febrile seizures seven to. 10 days after vaccination was about two times higher in children who ...<|separator|>
  156. [156]
    MMR or MMRV Vaccine: Discussing Options with Parents - CDC
    Unless the parent or caregiver expresses a preference for MMRV vaccine, CDC recommends that MMR vaccine and varicella vaccine should be administered as separate ...
  157. [157]
    What to Know About MMR and MMRV Vaccines | Johns Hopkins
    Sep 24, 2025 · Children grow out of this, and hence the reason why the MMRV vaccine can be given at the second dose,” says Moss.
  158. [158]
    The Vaccine - Measles & Rubella Partnership
    Today, the World Health Organization (WHO) recommends that children receive two doses of measles vaccine. The WHO also recommends that measles and rubella ...
  159. [159]
    Measles and Rubella Elimination - World Health Organization (WHO)
    All eleven Member countries in the Region are administering two-doses of measles containing vaccine (MCV) and at least one dose of rubella containing vaccine ( ...
  160. [160]
    MR-Vac - Measles & Rubella Vaccine (Live) I.P.
    MR-Vac - Measles & Rubella Vaccine (Live) I.P. manufactured by Serum Institute of India. ... MR vaccine is recommended in Infants, children, adolescents and ...
  161. [161]
    A phase II/III randomised, comparative study evaluating the safety ...
    Based on available study data, SIIL's combination Measles-Rubella vaccine is known to offer a mean sero-protection level of 96.43% and 91.67% for Measles and ...
  162. [162]
    Measles-rubella vaccine in Jordan is safe and effective at saving ...
    The measles-rubella (MR) vaccine, provided for targeted children in Jordan, is safe and effective at protecting children from deadly disease and outbreaks.
  163. [163]
    MEASLES & RUBELLA STRATEGIC FRAMEWORK 2021-2030
    Feb 23, 2021 · The goal for the 2021-2030 period is to “achieve and sustain the regional measles and rubella elimination goals”.
  164. [164]
    Cost-effectiveness of measles and rubella elimination in low-income ...
    Jul 10, 2023 · The objective of this paper is to present the findings of cost-effectiveness analysis (CEA) of ramping up MR vaccination with a goal of eliminating ...<|separator|>
  165. [165]
    Innovations in vaccine delivery: increasing access, coverage ... - NIH
    Measles-rubella (MR) vaccines are given by subcutaneous injection in a two-dose regimen as recommended by the World Health Organization (WHO). Before the use of ...
  166. [166]
    Achievements in Public Health: Elimination of Rubella and ... - CDC
    Mar 21, 2025 · This report summarizes the history and accomplishments of the rubella vaccination program in the United States and the Western Hemisphere
  167. [167]
    Region of the Americas is declared free of measles - PAHO/WHO
    Sep 27, 2016 · Washington, D.C., 27 September 2016 (PAHO/WHO) - The Region of the Americas is the first in the world to have eliminated measles, a viral ...
  168. [168]
    Global childhood immunization levels stalled in 2023, leaving many ...
    Jul 15, 2024 · However, the number of children who did not receive a single dose of the vaccine increased from 13.9 million in 2022 to 14.5 million in 2023.
  169. [169]
    https://www.cidrap.umn.edu/measles/us-measles-cases-top-1600-south-carolina-outbreak-grows
  170. [170]
    https://publications.aap.org/redbook/resources/15187/Red-Book-Online-Outbreaks-Measles
  171. [171]
    US kindergarten vaccination rates decline again - Healio
    Aug 1, 2025 · MMR coverage was 92.5% and DTaP coverage was 92.1% during the 2024-2025 school year. · Seventeen states reported exemption rates greater than 5%, ...
  172. [172]
    Two new studies predict results of declining MMR uptake, restricting ...
    Sep 22, 2025 · A modeling study estimates that a further 5% drop in kindergarten measles, mumps, and rubella (MMR) vaccination would substantially increase ...
  173. [173]
    A 30-fold rise of measles cases in 2023 in the WHO European ...
    Dec 14, 2023 · Over 30 000 measles cases were reported by 40 of the Region's 53 Member States between January and October 2023. Compared to 941 cases reported in all of 2022, ...
  174. [174]
    The Return of Measles: A Global Health Crisis Unfolding in 2025
    Sep 30, 2025 · In 2023 alone, 500,000 children across the European region missed their first dose of the measles vaccine.
  175. [175]
    Measles Cases in European Region Highest in More Than 25 Years
    Apr 18, 2025 · The World Health Organization (WHO) reported that measles cases in the European region more than doubled from 2023 to 2024, reaching about 127 ...
  176. [176]
    About Global Measles - CDC
    Jul 14, 2025 · Vaccine coverage of at least 95% with both doses of measles vaccine prevents outbreaks and protects communities. CDC works with countries and ...
  177. [177]
    The 2025 United States Measles Crisis: When Vaccine Hesitancy ...
    Jul 17, 2025 · In the U.S., the COVID-19 pandemic may have further fueled hesitancy ... MMR vaccination rates fall well below 90% before policy changes. In ...
  178. [178]
    Why Measles Is Making a Comeback Despite Available Vaccines
    May 18, 2025 · Vaccine hesitancy, which is the refusal or delayed acceptance of vaccines despite availability, has emerged as a key driver of the re-emergence ...
  179. [179]
    Estimating the number of US children susceptible to measles ...
    Children in birth cohorts from 2000 to 2017 failed to meet the herd immunity threshold for measles immunity of 92% [30]. This coverage estimate is based on a ...
  180. [180]
    Low Immunization Coverage Leads to Global Increase in Measles ...
    Mar 22, 2024 · In an IVAC webinar, a panel of experts discussed how the COVID-19 pandemic and vaccine hesitancy have contributed to an increase in measles ...Missing: 2020s | Show results with:2020s<|separator|>
  181. [181]
    [PDF] Chapter 13 - Vaccination Mandates: The Public Health ... - CDC
    Transmission in schools was recognized as a significant prob lem.22 In the early 1970s, states that had school vaccination laws for measles vaccine had measles ...
  182. [182]
    State Non-Medical Exemptions from School Immunization ...
    Fourteen states allow exemptions for either religious or personal reasons. Two states, Louisiana and Minnesota, do not specify whether the non-medical exemption ...
  183. [183]
    Measles Outbreak, New York City, 2018–2019
    Mar 11, 2020 · As a result of efforts to promote vaccination, the percentage of children in Williamsburg who received at least one dose of MMR vaccine ...
  184. [184]
    No Jab No Pay raises catch-up vaccination rates - NCIRS
    Oct 6, 2020 · The national “no jab, no pay” policy has been associated with substantial catch-up vaccination activity in lower socio-economic status areas.
  185. [185]
    No jab no pay raises catch up vaccination rates
    Oct 6, 2020 · The national 'No Jab No Pay' policy has seen an increase in catch-up vaccination rates, with some of the biggest changes in the lowest socio-economic status ...
  186. [186]
    Childhood Mandatory Vaccinations: Current Situation in European ...
    Nov 20, 2024 · These vaccines are mandatory in 10 countries, including Bulgaria, Croatia, the Czech Republic, France, Hungary, Italy, Latvia, Poland, Slovakia, ...
  187. [187]
    Global assessment of national mandatory vaccination policies and ...
    Nov 17, 2020 · We undertook a comprehensive assessment of national mandatory vaccination policies and identified a diversity of penalties in place to promote compliance.